Secondary analysis of CheckMate 227 and 9LA in metastatic NSCLC: progression or death within 3 months occurred in 40% on nivolumab plus ipilimumab vs 26% on chemotherapy, linked to high NLR, low TMB, PD-L1 <1% and low albumin; not seen with added chemotherapy.
Secondary analysis
Borghaei et al. Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer